Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALUR NASDAQ:IINN NASDAQ:NVNO NASDAQ:QNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.16-2.7%$2.64$1.98▼$22.25$16.77M-0.4670,588 shs32,837 shsIINNInspira Technologies OXY B.H.N.$1.15-2.5%$1.22$0.40▼$1.65$14.51M2.291.50 million shs435,125 shsNVNOenVVeno Medical$0.80-8.1%$3.95$0.77▼$5.70$15.39M0.881.98 million shs2.07 million shsQNRXQuoin Pharmaceuticals$7.67+2.3%$8.10$5.01▼$54.95$4.53M1.593,241 shs1,899 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies0.00%-3.91%-21.74%-21.60%-86.89%IINNInspira Technologies OXY B.H.N.0.00%-1.71%-6.50%+84.59%+6.48%NVNOenVVeno Medical0.00%-20.06%-83.59%-77.23%-84.80%QNRXQuoin Pharmaceuticals0.00%+5.44%+15.18%-12.23%-64.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALURAllurion Technologies2.5627 of 5 stars3.45.00.00.00.61.70.6IINNInspira Technologies OXY B.H.N.3.186 of 5 stars3.55.00.00.03.81.70.0NVNOenVVeno Medical0.7487 of 5 stars0.02.00.00.02.80.81.3QNRXQuoin Pharmaceuticals1.3413 of 5 stars0.04.00.00.02.70.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALURAllurion Technologies 2.80Moderate Buy$22.83957.10% UpsideIINNInspira Technologies OXY B.H.N. 3.00Buy$2.0073.91% UpsideNVNOenVVeno Medical 2.00HoldN/AN/AQNRXQuoin Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest QNRX, NVNO, ALUR, and IINN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025NVNOenVVeno MedicalLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/12/2025ALURAllurion TechnologiesZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold6/2/2025IINNInspira Technologies OXY B.H.N.Litchfield Hills ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/2/2025IINNInspira Technologies OXY B.H.N.Litchfield Hills ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$2.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALURAllurion Technologies$19.92M0.84N/AN/A($30.08) per share-0.07IINNInspira Technologies OXY B.H.N.N/AN/AN/AN/A$0.34 per shareN/ANVNOenVVeno MedicalN/AN/AN/AN/A$2.40 per shareN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/A$35.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALURAllurion Technologies-$7.20M-$12.53N/AN/AN/A-158.30%N/A-59.91%11/12/2025 (Estimated)IINNInspira Technologies OXY B.H.N.-$11.05MN/A0.00∞N/AN/AN/AN/AN/ANVNOenVVeno Medical-$21.82M-$1.20N/AN/AN/AN/A-57.35%-53.49%10/29/2025 (Estimated)QNRXQuoin Pharmaceuticals-$8.96M-$41.45N/AN/AN/AN/A-210.50%-99.41%11/6/2025 (Estimated)Latest QNRX, NVNO, ALUR, and IINN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025ALURAllurion Technologies-$0.65-$0.57+$0.08-$1.28$6.20 million$3.38 million8/7/2025Q2 2025QNRXQuoin Pharmaceuticals-$6.83-$6.28+$0.55-$6.28N/AN/A7/31/2025Q2 2025NVNOenVVeno Medical-$0.28-$0.33-$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALURAllurion TechnologiesN/AN/AN/AN/AN/AIINNInspira Technologies OXY B.H.N.N/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALURAllurion TechnologiesN/A2.021.70IINNInspira Technologies OXY B.H.N.0.092.021.89NVNOenVVeno MedicalN/A11.8111.81QNRXQuoin PharmaceuticalsN/A1.961.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALURAllurion Technologies21.39%IINNInspira Technologies OXY B.H.N.12.72%NVNOenVVeno Medical34.71%QNRXQuoin Pharmaceuticals8.63%Insider OwnershipCompanyInsider OwnershipALURAllurion Technologies22.40%IINNInspira Technologies OXY B.H.N.29.40%NVNOenVVeno Medical16.00%QNRXQuoin Pharmaceuticals13.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALURAllurion Technologies5017.76 million7.02 millionOptionableIINNInspira Technologies OXY B.H.N.2012.62 million8.91 millionNot OptionableNVNOenVVeno Medical3019.25 million16.17 millionOptionableQNRXQuoin Pharmaceuticals4590,000509,000Not OptionableQNRX, NVNO, ALUR, and IINN HeadlinesRecent News About These CompaniesQuoin Pharmaceuticals Announces CFO Departure AgreementAugust 27, 2025 | msn.comQuoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton SyndromeAugust 21, 2025 | markets.businessinsider.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization StrategyAugust 18, 2025 | finanznachrichten.deQuoin Pharmaceuticals appoints Lawlor as Chief Financial OfficerAugust 18, 2025 | msn.comQuoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization StrategyAugust 18, 2025 | globenewswire.comQuoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-EastonAugust 12, 2025 | globenewswire.comQNRX: Recent FDA & EMA Designations for QRX003 Potentially Could Accelerate TimelineAugust 8, 2025 | finance.yahoo.comQuoin (QNRX) Q2 Loss Beats EstimatesAugust 7, 2025 | fool.comQuoin Pharmaceuticals stock rises after positive clinical updatesJuly 31, 2025 | investing.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Product Portfolio UpdateJuly 29, 2025 | finanznachrichten.deQuoin Pharmaceuticals Provides Product Portfolio UpdateJuly 29, 2025 | globenewswire.comQuoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases - MorningstarJune 27, 2025 | morningstar.comMQuoin Pharmaceuticals Releases New Episode of NETHERTON NOW Featuring Expert Insights on Netherton Syndrome - NasdaqJune 27, 2025 | nasdaq.comQNRX - Quoin Pharmaceuticals Ltd ADR Executives - MorningstarJune 26, 2025 | morningstar.comMQuoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin DiseasesJune 26, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome - Yahoo FinanceJune 25, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton SyndromeJune 24, 2025 | tmcnet.comQuoin Pharmaceuticals, Ltd. (QNRX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comQNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand FurtherMay 29, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical StudyMay 22, 2025 | manilatimes.netMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQNRX, NVNO, ALUR, and IINN Company DescriptionsAllurion Technologies NYSE:ALUR$2.16 -0.06 (-2.70%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$2.17 +0.01 (+0.69%) As of 08/29/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.Inspira Technologies OXY B.H.N. NASDAQ:IINN$1.15 -0.03 (-2.54%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.14 0.00 (-0.43%) As of 08/29/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.enVVeno Medical NASDAQ:NVNO$0.80 -0.07 (-8.14%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$0.80 +0.01 (+0.70%) As of 08/29/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Quoin Pharmaceuticals NASDAQ:QNRX$7.67 +0.17 (+2.28%) Closing price 08/29/2025 03:41 PM EasternExtended Trading$7.61 -0.06 (-0.80%) As of 08/29/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
